Multiple sclerosis and related disorders · 2019
Glutamate and Nitric Oxide as biomarkers for disease activity in patients with multiple sclerosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdel Naseer Maged, Rabah Amany Mahmoud, Rashed Laila Ahmed, Hassan Amr, Fouad Amr M
Аннотация
BACKGROUND: Despite multiple diagnostic tests, multiple sclerosis (MS) remains a clinical diagnosis with supportive paraclinical evidence.
OBJECTIVE: To measure glutamate and nitric oxide serum levels in MS patients during and in between relapses to assess their potential role as biomarkers of disease activity and relapses.
SUBJECTS AND METHODS: This cross sectional study was carried out on 70 MS patients and 40 age and sex matched apparently healthy controls. MS patients were divided into 2 groups; group 1 that included thirty MS patients without history of relapse within the last 3 months prior to recruitment and group 2 that included forty MS patients with history of relapse within the last 30 day prior to recruitment.
RESULTS: Serum glutamate was significantly higher in group 2 (24.67 ± 9.58 μg/ml) compared to group 1(12.5 ± 4.9 μg/ml) (P value < 0.0001) and apparently healthy controls (3.5 ± 1.3 μg/ml) (P value < 0.0001). Serum nitric oxide was significantly higher in group 2 (84.87 ± 29.6 nmol/μl) than group 1 (41.99 ± 24.2 nmol/μl) (P value < 0.0001) and apparently healthy controls (12.03 ± 3.59 nmol/μl) (P value < 0.0001). Cutoff values of 17.5 μg/ml for glutamate and 75.2 nmol/μl for nitric oxide were found to predict occurrence of a relapse (sensitivity = 70% and 72.5% and specificity= 90% and 93.3% respectively).
CONCLUSION: Serum glutamate and nitric oxide can be potential easily-accessible biomarkers of disease activity and relapses in MS patients.
OBJECTIVE: To measure glutamate and nitric oxide serum levels in MS patients during and in between relapses to assess their potential role as biomarkers of disease activity and relapses.
SUBJECTS AND METHODS: This cross sectional study was carried out on 70 MS patients and 40 age and sex matched apparently healthy controls. MS patients were divided into 2 groups; group 1 that included thirty MS patients without history of relapse within the last 3 months prior to recruitment and group 2 that included forty MS patients with history of relapse within the last 30 day prior to recruitment.
RESULTS: Serum glutamate was significantly higher in group 2 (24.67 ± 9.58 μg/ml) compared to group 1(12.5 ± 4.9 μg/ml) (P value < 0.0001) and apparently healthy controls (3.5 ± 1.3 μg/ml) (P value < 0.0001). Serum nitric oxide was significantly higher in group 2 (84.87 ± 29.6 nmol/μl) than group 1 (41.99 ± 24.2 nmol/μl) (P value < 0.0001) and apparently healthy controls (12.03 ± 3.59 nmol/μl) (P value < 0.0001). Cutoff values of 17.5 μg/ml for glutamate and 75.2 nmol/μl for nitric oxide were found to predict occurrence of a relapse (sensitivity = 70% and 72.5% and specificity= 90% and 93.3% respectively).
CONCLUSION: Serum glutamate and nitric oxide can be potential easily-accessible biomarkers of disease activity and relapses in MS patients.